RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3B/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS

被引：12

作者：

Charles-Schoeman, C. ^{[1
]}

Fleischmann, R. M. ^{[2
]}

Mysler, E. ^{[3
]}

Greenwald, M. ^{[4
]}

Wang, C. ^{[5
]}

Chen, A. S. ^{[5
]}

Connell, C. A. ^{[5
]}

Woolcott, J. ^{[6
]}

Menon, S. ^{[5
]}

Chen, Y. ^{[7
]}

Lee, K. ^{[7
]}

Szekanecz, Z. ^{[8
]}

机构：

[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA

[2] Univ Texas SouthWestern Med Ctr, Metroplex Clin Res Ctr, Dept Internal Med, Dallas, TX USA

[3] Organizac Medica Invest, Rheumatol, Buenos Aires, DF, Argentina

[4] Desert Med Adv, Rheumatol, Palm Desert, CA USA

[5] Pfizer Inc, Inflammat & Immunol, Groton, CT USA

[6] Pfizer Inc, Inflammat & Immunol, Collegeville, PA USA

[7] Pfizer Inc, Inflammat & Immunol, New York, NY USA

[8] Univ Debrecen, Div Rheumatol, Fac Med, Debrecen, Hungary

来源：

关键词：

D O I：

10.1136/annrheumdis-2022-eular.1016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0239

引用

页码：358 / 359

页数：2